Loading
Life sciences · Journal article
Frontiers in Bioengineering and Biotechnology · October 12, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Chimeric antigen receptor (CAR) T cell therapy is considered a therapeutic breakthrough in hematological malignancies. However, its translation to metastasized solid tumors remains limited by the paucity of “druggable” targets and the limited therapeutic potency of the cell therapeutics in solid cancers. Human epidermal growth factor receptor 2 (HER2), a promising target for treatment of metastasized solid cancers, is amplified in around 3% (HER2 + cancer) and overexpressed without amplification in ∼40% (HER2 low cancer) of all carcinomas, yet the physiological expression of HER2 on healthy tissues poses the risk of on-target off-tumor effects. To address this, we utilized low-affinity (LA) Anti-HER2-CAR T cells. These CAR T cells exhibited efficient lysis of HER2 + SKOV3 ovarian cancer cells even at low effector-to-target ratios. Following stimulation through cancer cells, LA Anti-HER2-CAR T cells showed rapid proliferation and elevation of pro-inflammatory cytokines markers. Low numbers of CAR T cells were sufficient to induce durable complete remissions of systemically seeded ovarian cancer in NOD- Prkdc scid -IL2rg Tm1 /Rj mice. LA Anti-HER2 CAR T cells also exhibited tumor regression and lasting tumor control in a subcutaneous in vivo model of HER2 low LS174T cells. Additionally, the LA and high-affinity (HA) CAR T cells could effectively combat HER2 low human colorectal cancer (CRC) cell lines and primary CRC organoids, while LA Anti-HER2-CAR T cells showed a trend-wise reduced lysis of healthy colon organoids. Our results suggest that LA Anti-HER2-CAR T cells provide a novel treatment option for HER2-overexpressing advanced systemic tumors. Importantly, they effectively distinguished between healthy colon tissue and HER2 low cancer, broadening the scope of HER2-directed CAR T cells to this frequent cancer subset.